Current Challenges in Chimeric Antigen Receptor T-cell Therapy in Patients With B-cell Lymphoid Malignancies

키워드

참고문헌 (87)

1. Ramos CA, "Chimeric antigen receptor(CAR)-engineered lymphocytes for cancer therapy", Expert Opin Biol Ther, 11, pp.855~873 (2011)
2. Zhang C, "Engineering CAR-T cells", Biomark Res, 5, pp.22~ (2017)
3. Jackson HJ, "Driving CAR T-cells forward", Nat Rev Clin Oncol, 13, pp.370~383 (2016)
4. Schuster SJ, "Tisagenlecleucel in adult relapsed or refractory diffuse large B-cell lymphoma", N Engl J Med, 380, pp.45~56 (2019)
5. Maude SL, "Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia", N Engl J Med, 378, pp.439~448 (2018)
6. Fowler NH, "Tisagenlecleucel in adult relapsed or refractory follicular lymphoma : the phase 2 ELARA trial", Nat Med, 28, pp.325~332 (2022)
7. Neelapu SS, "Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma", N Engl J Med, 377, pp.2531~2544 (2017)
8. Jacobson CA, "Axicabtagene ciloleucel in relapsed or refractory indolent non-Hodgkin lymphoma (ZUMA-5): a single-arm, multicentre, phase 2 trial", Lancet Oncol, 23, pp.91~103 (2022)
9. Shah BD, "KTE-X19 for relapsed or refractory adult B-cell acute lymphoblastic leukaemia: phase 2 results of the single-arm, open-label, multicentre ZUMA-3 study", Lancet, 398, pp.491~502 (2021)
10. Wang M, "KTE-X19CAR T-cell therapy in relapsed or refractory mantle-cell lymphoma", N Engl J Med, 382, pp.1331~1342 (2020)
11. Abramson JS, "Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas(TRANSCEND NHL 001) : a multicentre seamless design study", Lancet, 396, pp.839~852 (2020)
12. Locke FL, "Axicabtagene ciloleucel as second-line therapy for large B-cell lymphoma", N Engl J Med, 386, pp.640~654 (2022)
13. Kamdar M, "Lisocabtagene maraleucel versus standard of care with salvage chemotherapy followed by autologous stem cell transplantation as second-line treatment in patients with relapsed or refractory large B-cell lymphoma (TRANSFORM): results from an interim analysis of an openlabel, randomised, phase 3 trial", Lancet, 399, pp.2294~2308 (2022)
14. Munshi NC, "Idecabtagene vicleucel in relapsed and refractory multiple myeloma", N Engl J Med, 384, pp.705~716 (2021)
15. Berdeja JG, "Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b", 2 open-label study, 2021, pp.398, 314~324
16. Bücklein V, "Inferior outcomes of EU versus US patients treated with CD19 CAR-T for relapsed", refractory large B-cell lymphoma : association with differences in tumor burden, systemic inflammation, bridging therapy utilization, and CAR-T product use, 2023, pp.7, e907~
17. Hoffmann MS, "Overcoming barriers to referral for chimeric antigen receptor T cell therapy in patients with relapsed", refractory diffuse large B cell lymphoma, 2023, pp.29, 440~448
18. Bethge WA, "GLA", DRST real-world outcome analysis of CAR T-cell therapies for large B-cell lymphoma in Germany, 2022, pp.140, 349~358
19. Zafar A, "Intensity of cyclophosphamide-based bridging therapy before chimeric antigen receptor T cell therapy in myeloma", Transplant Cell Ther, 29, pp.504~ (2023)
20. Ladbury C, "Long-term follow-up of bridging therapies prior to CAR T-cell therapy for relapsed", refractory large B cell lymphoma, 2023, pp.15, 1747~
21. Roddie C, "Effective bridging therapy can improve CD19 CAR-T outcomes while maintaining safety in patients with large B-cell lymphoma", Blood Adv, 7, pp.2872~2883 (2023)
22. Hirayama AV, "The response to lymphodepletion impacts PFS in patients with aggressive non-Hodgkin lymphoma treated with CD19 CAR T cells", Blood, 133, pp.1876~1887 (2019)
23. Byun JM, "Practical issues in CAR T-cell therapy", Blood Res, 58, pp.S11~S12 (2023)
24. Fried S, "Early and late hematologic toxicity following CD19 CAR-T cells", Bone Marrow Transplant, 54, pp.1643~1650 (2019)
25. Yoo JW, "Management of adverse events in young adults and children with acute B-cell lymphoblastic leukemia receiving anti-CD19 chimeric antigen receptor(CAR)T-cell therapy", Blood Res, 58, pp.S20~S28 (2023)
26. Li Y, "The pathogenesis, diagnosis, prevention, and treatment of CAR-T cell therapy-related adverse reactions", Front Pharmacol, 13, pp.950923~ (2022)
27. Neelapu SS, "Chimeric antigen receptor T-cell therapy — assessment and management of toxicities", Nat Rev Clin Oncol, 15, pp.47~62 (2018)
28. Norelli M, "Monocyte-derived IL-1 and IL-6 are differentially required for cytokine-release syndrome and neurotoxicity due to CAR T cells", Nat Med, 24, pp.739~748 (2018)
29. Grupp SA, "Chimeric antigen receptor-modified T cells for acute lymphoid leukemia", N Engl J Med, 368, pp.1509~1518 (2013)
30. Si S, "Spotlight on tocilizumab in the treatment of CAR-Tcell-induced cytokine release syndrome : clinical evidence to date", Ther Clin Risk Manag, 16, pp.705~714 (2020)
31. Le RQ, "FDA approval summary : tocilizumab for treatment of chimeric antigen receptor T cell-induced severe or life-threatening cytokine release syndrome", Oncologist, 23, pp.943~947 (2018)
32. Lee DW, "ASTCT consensus grading for cytokine release syndrome and neurologic toxicity associated with immune effector cells", Biol Blood Marrow Transplant, 25, pp.625~638 (2019)
33. Santomasso BD, "Management of immune-related adverse events in patients treated with chimeric antigen receptor T-cell therapy : ASCO Guideline", J Clin Oncol, 39, pp.3978~3992 (2021)
34. Santomasso BD, "Clinical and biological correlates of neurotoxicity associated with CAR Tcell therapy in patients with B-cell acute lymphoblastic leukemia", Cancer Discov, 8, pp.958~971 (2018)
35. Freyer CW, "Cytokine release syndrome and neurotoxicity following CAR T-cell therapy for hematologic malignancies", J Allergy Clin Immunol, 146, pp.940~948 (2020)
36. Gust J, "Endothelial activation and blood-brain barrier disruption in neurotoxicity after adoptive immunotherapy with CD19 CAR-T cells", Cancer Discov, 7, pp.1404~1419 (2017)
37. Gust J, "Cytokines in CAR T cellassociated neurotoxicity", Front Immunol, 11, pp.577027~ (2020)
38. Lee DW, "T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults : a phase 1 dose-escalation trial", Lancet, 385, pp.517~528 (2015)
39. Nastoupil LJ, "Standard-of-care axicabtagene ciloleucel for relapsed or refractory large Bcell lymphoma : results from the US lymphoma CAR T Consortium", J Clin Oncol, 38, pp.3119~3128 (2020)
40. Holtzman NG, "Immune effector cell-associated neurotoxicity syndrome after chimeric antigen receptor T-cell therapy for lymphoma : predictive biomarkers and clinical outcomes", Neuro Oncol, 23, pp.112~121 (2021)
41. Nellan A, "Improved CNS exposure to tocilizumab after cerebrospinal fluid compared to intravenous administration in rhesus macaques", Blood, 132, pp.662~666 (2018)
42. Neelapu SS, "Managing the toxicities of CAR T-cell therapy", Hematol Oncol, 37(Suppl 1), pp.48~52 (2019)
43. Schubert ML, "Side-effect management of chimeric antigen receptor(CAR)T-cell therapy", Ann Oncol, 32, pp.34~48 (2021)
44. Topp MS, "Earlier corticosteroid use for adverse event management in patients receiving axicabtagene ciloleucel for large B-cell lymphoma", Br J Haematol, 195, pp.388~398 (2021)
45. Wehrli M, "Single-center experience using anakinra for steroid-refractory immune effector cell-associated neurotoxicity syndrome(ICANS)", J Immunother Cancer, 10, pp.e003847~ (2022)
46. Riegler LL, "Current approaches in the grading and management of cytokine release syndrome after chimeric antigen receptor T-cell therapy", Ther Clin Risk Manag, 15, pp.323~335 (2019)
47. Hines MR, "Hemophagocytic lymphohistiocytosis-like toxicity(carHLH)after CD19-specific CAR T-cell therapy", Br J Haematol, 194, pp.701~707 (2021)
48. Major A, "Management of hemophagocytic lymphohistiocytosis(HLH)associated with chimeric antigen receptor T-cell(CAR-T)therapy using anti-cytokine therapy : an illustrative case and review of the literature", Leuk Lymphoma, 62, pp.1765~1769 (2021)
49. Hines MR, "Immune effector cell-associated hemophagocytic lymphohistiocytosislike syndrome", Transplant Cell Ther, 29, pp.438~ (2023)
50. Henter JI, "Treatment of hemophagocytic lymphohistiocytosis with HLH-94 immunochemotherapy and bone marrow transplantation", Blood, 100, pp.2367~2373 (2002)
51. Rosado FGN, "Hemophagocytic lymphohistiocytosis : an update on diagnosis and pathogenesis", Am J Clinical Pathol, 139, pp.713~727 (2013)
52. Sandler RD, "Diagnosis and management of secondary HLH", MAS following HSCT and CAR-T cell therapy in adults; a review of the literature and a survey of practice within EBMT centres on behalf of the autoimmune diseases working party(ADWP)and transplant complications working party(TCWP), 2020, pp.11, 524~
53. Henter JI, "HLH-2004 : diagnostic and therapeutic guidelines for hemophagocytic lymphohistiocytosis", Pediatr Blood Cancer, 48, pp.124~131 (2007)
54. Daver N, "Malignancy-associated haemophagocytic lymphohistiocytosis in adults", Lancet Oncol, 18, pp.169~171 (2017)
55. Yoon SE, "A comprehensive analysis of adult patients with secondary hemophagocytic lymphohistiocytosis : a prospective cohort study", Ann Hematol, 99, pp.2095~2104 (2020)
56. Thompson JA, "Management of Immunotherapy-Related Toxicities, Version 1.2022, NCCN Clinical Practice Guidelines in Oncology", J Natl Compr Canc Netw, 20, pp.387~405 (2022)
57. Rainone M, "Interferongamma blockade in CAR T-cell therapy-associated macrophage activation syndrome", hemophagocytic lymphohistiocytosis, 2023, pp.7, 533~536
58. La Rosée P, "Recommendations for the management of hemophagocytic lymphohistiocytosis in adults", Blood, 133, pp.2465~2477 (2019)
59. Nahas GR, "Incidence and risk factors associated with a syndrome of persistent cytopenias after CAR-T cell therapy(PCTT)", Leuk Lymphoma, 61, pp.940~943 (2020)
60. Jain T, "How I treat cytopenias after CAR T-cell therapy", Blood, 141, pp.2460~2469 (2023)
61. Juluri KR, "Severe cytokine release syndrome is associated with hematologic toxicity following CD19 CAR T-cell therapy", Blood Adv, 6, pp.2055~2068 (2022)
62. Rejeski K, "Oligoclonal T-cell expansion in a patient with bone marrow failure after CD19 CAR-T therapy for Richter-transformed DLBCL", Blood, 140, pp.2175~2179 (2022)
63. Rejeski K, "CARHEMATOTOX : a model for CAR T-cell-related hematologic toxicity in relapsed", refractory large B-cell lymphoma, 2021, pp.138, 2499~2513
64. Rejeski K, "The CAR-HEMATOTOX risk-stratifies patients for severe infections and disease progression after CD19 CAR-T in R", R LBCL, 2022, pp.10, e004475~
65. Rejeski K, "Immune effector cell-associated hematotoxicity : EHA", EBMT consensus grading and best practice recommendations, 2023, pp.142, 865~877
66. Galli E, "G-CSF does not worsen toxicities and efficacy of CAR-T cells in refractory", relapsed B-cell lymphoma, 2020, pp.55, 2347~2349
67. Liévin R, "Effect of early granulocyte-colony-stimulating factor administration in the prevention of febrile neutropenia and impact on toxicity and efficacy of anti-CD19 CAR-T in patients with relapsed", refractory B-cell lymphoma, 2022, pp.57, 431~439
68. Lemoine J, "Non-relapse mortality after CAR T-cell therapy for large B-cell lymphoma : a LYSA study from the DESCAR-T Registry", Blood Adv, 7, pp.6589~6598 (2023)
69. Bivona G, "Biomarkers for prognosis and treatment response in COVID-19 patients", Ann Lab Med, 41, pp.540~548 (2021)
70. Harris CE, "COVID-19and other viral infections in patients with hematologic malignancies", Am Soc Clin Oncol Educ Book, 43, pp.e390778~ (2023)
71. Shalabi H, "Sequential loss of tumor surface antigens following chimeric antigen receptor T-cell therapies in diffuse large B-cell lymphoma", Haematologica, 103, pp.e215~e218 (2018)
72. Plaks V, "CD19 target evasion as a mechanism of relapse in large B-cell lymphoma treated with axicabtagene ciloleucel", Blood, 138, pp.1081~1085 (2021)
73. Shah NN, "Longterm follow-up of CD19-CAR T-cell therapy in children and young adults with B-ALL", J Clin Oncol, 39, pp.1650~1659 (2021)
74. Park JH, "Longterm follow-up of CD19 CAR therapy in acute lymphoblastic leukemia", N Engl J Med, 378, pp.449~459 (2018)
75. Myers RM, "Blinatumomab nonresponse and high-disease burden are associated with inferior outcomes after CD19-CAR for B-ALL", J Clin Oncol, 40, pp.932~944 (2022)
76. Singh N, "Impaired death receptor signaling in leukemia causes antigen-independent resistance by inducing CAR T-cell dysfunction", Cancer Discov, 10, pp.552~567 (2020)
77. Dekker L, "Fludarabine exposure predicts outcome after CD19 CAR T-cell therapy in children and young adults with acute leukemia", Blood Adv, 6, pp.1969~1976 (2022)
78. Jain MD, "Tumor interferon signaling and suppressive myeloid cells are associated with CAR T-cell failure in large B-cell lymphoma", Blood, 137, pp.2621~2633 (2021)
79. Mehta PH, "T cell fitness and autologous CAR T cell therapy in haematologic malignancy", Front Immunol, 12, pp.780442~ (2021)
80. Scholler N, "Tumor immune contexture is a determinant of anti-CD19 CAR T cell efficacy in large B cell lymphoma", Nat Med, 28, pp.1872~1882 (2022)
81. Deng Q, "Characteristics of anti-CD19 CAR T cell infusion products associated with efficacy and toxicity in patients with large B cell lymphomas", Nat Med, 26, pp.1878~1887 (2020)
82. Sommermeyer D, "Chimeric antigen receptor-modified T cells derived from defined CD8+ and CD4+ subsets confer superior antitumor reactivity in vivo", Leukemia, 30, pp.492~500 (2016)
83. Gattinoni L, "A human memory T cell subset with stem cell-like properties", Nat Med, 17, pp.1290~1297 (2011)
84. Gattinoni L, "T memory stem cells in health and disease", Nat Med, 23, pp.18~27 (2017)
85. Alvarez-Fernàndez C, "Memory stem T cells modified with a redesigned CD30-chimeric antigen receptor show an enhanced antitumor effect in Hodgkin lymphoma", Clin Transl Immunology, 10, pp.e1268~ (2021)
86. Locke FL, "Tumor burden, inflammation, and product attributes determine outcomes of axicabtagene ciloleucel in large B-cell lymphoma", Blood Adv, 4, pp.4898~4911 (2020)
87. Aldoss I, "Favorable activity and safety profile of memory-enriched CD19-targeted chimeric antigen receptor T-cell therapy in adults with high-risk relapsed", refractory ALL, 2023, pp.29, 742~753

관련 논문AI추천